Inflammatory genes in epicardial fat contiguous with coronary atherosclerosis in the metabolic syndrome and type 2 diabetes

Changes associated with pioglitazone

Harold S. Sacks, John N. Fain, Paramjeet Cheema, Suleiman Bahouth, Edward Garrett, Rodney Y. Wolf, David Wolford, Joseph Samaha

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

OBJECTIVE - To determine changes in gene expression in epicardial adipose tissue (EAT) associated with coronary atherosclerosis (CAD) and effects of pioglitazone therapy. RESEARCH DESIGN AND METHODS - Genes were quantified by RT-PCR in EAT and thoracic subcutaneous adipose tissue (SAT) obtained during surgery in CAD patients with metabolic syndrome (MS) or type 2 diabetes and control subjects with minimal or no CAD and no MS or type 2 diabetes. RESULTS - Increased expression of interleukin-1 receptor antagonist (IL-1Ra) and IL-10, a trend for higher IL-1β, and no change in peroxisome proliferator-activated receptor-γ (PPARγ) was found in EAT from MS or type 2 diabetes. Only PPARγ mRNA was reduced in SAT. Pioglitazone therapy in type 2 diabetes was associated with decreased expression of IL-1β, IL-1Ra, and IL-10 in EAT; decreased IL-10 in SAT; and increased PPARγ in SAT. CONCLUSIONS - In MS and type 2 diabetes with CAD, proinflammatory and antiinflammatory genes were differentially increased in EAT and selectively reduced in association with pioglitazone treatment.

Original languageEnglish (US)
Pages (from-to)730-733
Number of pages4
JournalDiabetes Care
Volume34
Issue number3
DOIs
StatePublished - Mar 1 2011

Fingerprint

pioglitazone
Type 2 Diabetes Mellitus
Subcutaneous Fat
Adipose Tissue
Coronary Artery Disease
Fats
Peroxisome Proliferator-Activated Receptors
Interleukin-10
Interleukin-1 Receptors
Genes
Interleukin-1
Anti-Inflammatory Agents
Research Design
Thorax
Therapeutics
Gene Expression
Polymerase Chain Reaction
Messenger RNA

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Inflammatory genes in epicardial fat contiguous with coronary atherosclerosis in the metabolic syndrome and type 2 diabetes : Changes associated with pioglitazone. / Sacks, Harold S.; Fain, John N.; Cheema, Paramjeet; Bahouth, Suleiman; Garrett, Edward; Wolf, Rodney Y.; Wolford, David; Samaha, Joseph.

In: Diabetes Care, Vol. 34, No. 3, 01.03.2011, p. 730-733.

Research output: Contribution to journalArticle

Sacks, Harold S. ; Fain, John N. ; Cheema, Paramjeet ; Bahouth, Suleiman ; Garrett, Edward ; Wolf, Rodney Y. ; Wolford, David ; Samaha, Joseph. / Inflammatory genes in epicardial fat contiguous with coronary atherosclerosis in the metabolic syndrome and type 2 diabetes : Changes associated with pioglitazone. In: Diabetes Care. 2011 ; Vol. 34, No. 3. pp. 730-733.
@article{57a8c6afb35144a0a97a5209c918d83d,
title = "Inflammatory genes in epicardial fat contiguous with coronary atherosclerosis in the metabolic syndrome and type 2 diabetes: Changes associated with pioglitazone",
abstract = "OBJECTIVE - To determine changes in gene expression in epicardial adipose tissue (EAT) associated with coronary atherosclerosis (CAD) and effects of pioglitazone therapy. RESEARCH DESIGN AND METHODS - Genes were quantified by RT-PCR in EAT and thoracic subcutaneous adipose tissue (SAT) obtained during surgery in CAD patients with metabolic syndrome (MS) or type 2 diabetes and control subjects with minimal or no CAD and no MS or type 2 diabetes. RESULTS - Increased expression of interleukin-1 receptor antagonist (IL-1Ra) and IL-10, a trend for higher IL-1β, and no change in peroxisome proliferator-activated receptor-γ (PPARγ) was found in EAT from MS or type 2 diabetes. Only PPARγ mRNA was reduced in SAT. Pioglitazone therapy in type 2 diabetes was associated with decreased expression of IL-1β, IL-1Ra, and IL-10 in EAT; decreased IL-10 in SAT; and increased PPARγ in SAT. CONCLUSIONS - In MS and type 2 diabetes with CAD, proinflammatory and antiinflammatory genes were differentially increased in EAT and selectively reduced in association with pioglitazone treatment.",
author = "Sacks, {Harold S.} and Fain, {John N.} and Paramjeet Cheema and Suleiman Bahouth and Edward Garrett and Wolf, {Rodney Y.} and David Wolford and Joseph Samaha",
year = "2011",
month = "3",
day = "1",
doi = "10.2337/dc10-2083",
language = "English (US)",
volume = "34",
pages = "730--733",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "3",

}

TY - JOUR

T1 - Inflammatory genes in epicardial fat contiguous with coronary atherosclerosis in the metabolic syndrome and type 2 diabetes

T2 - Changes associated with pioglitazone

AU - Sacks, Harold S.

AU - Fain, John N.

AU - Cheema, Paramjeet

AU - Bahouth, Suleiman

AU - Garrett, Edward

AU - Wolf, Rodney Y.

AU - Wolford, David

AU - Samaha, Joseph

PY - 2011/3/1

Y1 - 2011/3/1

N2 - OBJECTIVE - To determine changes in gene expression in epicardial adipose tissue (EAT) associated with coronary atherosclerosis (CAD) and effects of pioglitazone therapy. RESEARCH DESIGN AND METHODS - Genes were quantified by RT-PCR in EAT and thoracic subcutaneous adipose tissue (SAT) obtained during surgery in CAD patients with metabolic syndrome (MS) or type 2 diabetes and control subjects with minimal or no CAD and no MS or type 2 diabetes. RESULTS - Increased expression of interleukin-1 receptor antagonist (IL-1Ra) and IL-10, a trend for higher IL-1β, and no change in peroxisome proliferator-activated receptor-γ (PPARγ) was found in EAT from MS or type 2 diabetes. Only PPARγ mRNA was reduced in SAT. Pioglitazone therapy in type 2 diabetes was associated with decreased expression of IL-1β, IL-1Ra, and IL-10 in EAT; decreased IL-10 in SAT; and increased PPARγ in SAT. CONCLUSIONS - In MS and type 2 diabetes with CAD, proinflammatory and antiinflammatory genes were differentially increased in EAT and selectively reduced in association with pioglitazone treatment.

AB - OBJECTIVE - To determine changes in gene expression in epicardial adipose tissue (EAT) associated with coronary atherosclerosis (CAD) and effects of pioglitazone therapy. RESEARCH DESIGN AND METHODS - Genes were quantified by RT-PCR in EAT and thoracic subcutaneous adipose tissue (SAT) obtained during surgery in CAD patients with metabolic syndrome (MS) or type 2 diabetes and control subjects with minimal or no CAD and no MS or type 2 diabetes. RESULTS - Increased expression of interleukin-1 receptor antagonist (IL-1Ra) and IL-10, a trend for higher IL-1β, and no change in peroxisome proliferator-activated receptor-γ (PPARγ) was found in EAT from MS or type 2 diabetes. Only PPARγ mRNA was reduced in SAT. Pioglitazone therapy in type 2 diabetes was associated with decreased expression of IL-1β, IL-1Ra, and IL-10 in EAT; decreased IL-10 in SAT; and increased PPARγ in SAT. CONCLUSIONS - In MS and type 2 diabetes with CAD, proinflammatory and antiinflammatory genes were differentially increased in EAT and selectively reduced in association with pioglitazone treatment.

UR - http://www.scopus.com/inward/record.url?scp=79956127761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956127761&partnerID=8YFLogxK

U2 - 10.2337/dc10-2083

DO - 10.2337/dc10-2083

M3 - Article

VL - 34

SP - 730

EP - 733

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 3

ER -